Prognostic Value of the Largest Lesion Size for Progression-Free Survival in Patients with NET Undergoing Salvage PRRT with [

DOTATOC De Ritis ratio PRRT lesion size neuroendocrine tumor salvage PRRT

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
31 Mar 2022
Historique:
received: 21 02 2022
revised: 25 03 2022
accepted: 28 03 2022
entrez: 12 4 2022
pubmed: 13 4 2022
medline: 13 4 2022
Statut: epublish

Résumé

(1) Background: retreatment with radionuclide-labeled somatostatin analogues following disease progression after initial treatment cycles is often referred to as salvage peptide receptor radionuclide therapy (salvage PRRT). Salvage PRRT is shown to have a favorable safety profile in patients with metastatic neuroendocrine tumors (NETs), but numerous questions about the efficacy and prognostic or predictive factors remain to be answered. The purpose of this study was to evaluate two parameters that have shown prognostic significance in progression-free survival (PFS) in initial PRRT treatment, namely the size of the largest lesion (LLS) and the De Ritis ratio (aspartate aminotransferase (AST)/alanine aminotransferase (ALT)), as prognostic factors in the context of salvage PRRT. In addition, the PFS after initial PRRT was evaluated as a predictor of the PFS following salvage PRRT. (2) Methods: retrospective, monocentric analysis in 32 patients with NETs (gastroenteropancreatic, 23; unknown primary, 7; kidney, 1; lung, 1) and progression after initial PRRT undergoing retreatment with [

Identifiants

pubmed: 35406540
pii: cancers14071768
doi: 10.3390/cancers14071768
pmc: PMC8996884
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Eur J Nucl Med Mol Imaging. 2014 Feb;41(2):205-10
pubmed: 24030668
Comput Math Methods Med. 2013;2013:745742
pubmed: 24454541
Nucl Med Commun. 2021 Apr 1;42(4):451-458
pubmed: 33346603
Medicine (Baltimore). 2016 Jun;95(24):e3843
pubmed: 27310963
EMBO J. 2017 May 15;36(10):1302-1315
pubmed: 28420743
BMC Cancer. 2019 Aug 8;19(1):788
pubmed: 31395036
J Nucl Med. 2010 Mar;51(3):383-90
pubmed: 20150247
J Nucl Med. 2001 Dec;42(12):1841-6
pubmed: 11752083
Cancer Treat Rev. 2021 Feb;93:102141
pubmed: 33418096
World J Radiol. 2013 Jun 28;5(6):241-7
pubmed: 23807902
Neuropsychiatr Dis Treat. 2017 Jun 15;13:1551-1557
pubmed: 28670124
Ther Adv Med Oncol. 2020 Apr 10;12:1758835919900872
pubmed: 32313566
Clin Genitourin Cancer. 2017 Jun;15(3):e379-e385
pubmed: 27692696
Oncotarget. 2018 Feb 15;9(24):16932-16950
pubmed: 29682195
Neoplasia. 2017 Dec;19(12):991-1002
pubmed: 29091800
Br J Radiol. 2018 Nov;91(1091):20180041
pubmed: 29513039
Mod Pathol. 2018 Dec;31(12):1770-1786
pubmed: 30140036
Cancers (Basel). 2021 Feb 05;13(4):
pubmed: 33562643
Clin Chim Acta. 1989 Dec 15;185(3):265-70
pubmed: 2620458
Breast Cancer Res. 2008;10(5):R84
pubmed: 18922152
Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2372-2382
pubmed: 32123969
J Nucl Med. 2005 Jan;46 Suppl 1:13S-7S
pubmed: 15653647
Exp Cell Res. 2003 Feb 1;283(1):1-16
pubmed: 12565815
Clin Biochem Rev. 2013 Nov;34(3):117-30
pubmed: 24353357
J Nucl Med. 1995 Oct;36(10):1902-9
pubmed: 7562062
EXCLI J. 2016 Dec 15;15:817-828
pubmed: 28337112
PLoS One. 2012;7(12):e51862
pubmed: 23251644
Int Urol Nephrol. 2017 Aug;49(8):1391-1398
pubmed: 28550473
Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1207-1214
pubmed: 28246882
EMBO Rep. 2018 Jun;19(6):
pubmed: 29661856
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):704-717
pubmed: 30267116
Gastroenterology. 2008 Dec;135(6):1935-44, 1944.e1
pubmed: 19010326
Cell Cycle. 2013 Jul 1;12(13):1987-8
pubmed: 23759579
Langenbecks Arch Surg. 2011 Dec;396(8):1145-56
pubmed: 21523447
Gastroenterology. 2010 Sep;139(3):742-53, 753.e1
pubmed: 20637207
World J Gastrointest Oncol. 2020 Aug 15;12(8):893-902
pubmed: 32879666
Neuroendocrinology. 2014;100(2-3):221-7
pubmed: 25358267
Eur J Nucl Med Mol Imaging. 2014 May;41(5):925-33
pubmed: 24504504
Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):1955-63
pubmed: 26112388
Eur J Radiol. 2015 Aug;84(8):1436-1443
pubmed: 26022520

Auteurs

Markus Galler (M)

Department of Nuclear Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.

Julian M M Rogasch (JMM)

Department of Nuclear Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.

Kai Huang (K)

Department of Nuclear Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.

Henning Jann (H)

Department of Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.

Kristina Plehm (K)

Department of Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.

Christoph Wetz (C)

Department of Nuclear Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.

Holger Amthauer (H)

Department of Nuclear Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.

Classifications MeSH